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Abstract
Introduction: The function of interleukin-18 (IL-18) was investigated in pertinent animal models of rodent rheumatoid 
arthritis (RA) to determine its proinflammatory and monocyte recruitment properties.
Methods: We used a modified Boyden chemotaxis system to examine monocyte recruitment to recombinant human 
(rhu) IL-18 in vitro. Monocyte recruitment to rhuIL-18 was then tested in vivo by using an RA synovial tissue (ST) severe 
combined immunodeficient (SCID) mouse chimera. We defined monocyte-specific signal-transduction pathways 
induced by rhuIL-18 with Western blotting analysis and linked this to in vitro monocyte chemotactic activity. Finally, the 
ability of IL-18 to induce a cytokine cascade during acute joint inflammatory responses was examined by inducing 
wild-type (Wt) and IL-18 gene-knockout mice with zymosan-induced arthritis (ZIA).
Results: We found that intragraft injected rhuIL-18 was a robust monocyte recruitment factor to both human ST and 
regional (inguinal) murine lymph node (LN) tissue. IL-18 gene-knockout mice also showed pronounced reductions in 
joint inflammation during ZIA compared with Wt mice. Many proinflammatory cytokines were reduced in IL-18 gene-
knockout mouse joint homogenates during ZIA, including macrophage inflammatory protein-3α (MIP-3α/CCL20), 
vascular endothelial cell growth factor (VEGF), and IL-17. Signal-transduction experiments revealed that IL-18 signals 
through p38 and ERK½ in monocytes, and that IL-18-mediated in vitro monocyte chemotaxis can be significantly 
inhibited by disruption of this pathway.
Conclusions: Our data suggest that IL-18 may be produced in acute inflammatory responses and support the notion 
that IL-18 may serve a hierarchic position for initiating joint inflammatory responses.
Introduction
Interleukin-18 (IL-18) is a type-1 cytokine associated
with proinflammatory properties. IL-18 is present at
increased levels in serum and in the rheumatoid syn-
ovium, as well as in the bone marrow in many human
rheumatologic conditions, including rheumatoid arthritis
(RA), juvenile RA, adult-onset Still disease, and psoriatic
arthritis [1-27]. Interestingly, rheumatoid nodules have
features of type-1 (Th1) granulomas [1,28,29] with abun-
dant expression of type-1 inflammatory cytokines,
including interferon-γ (IFN-γ) and IL-18 [1,30]. IL-18
also induces the release of type 1 cytokines by T cells and
macrophages and stimulates production of inflammatory
mediators, such as chemokines, by synovial fibroblasts or
nitric oxide by macrophages and chondrocytes [31-35].
Among other cytokines, IL-18 is thought to play a pivotal
role in the inflammatory cascade in patients with adult-
onset Still disease by orchestrating the Th1 response and
inducing other cytokines, such as IL-1β, IL-8, tumor
necrosis factor-α TNF-α and IFN-γ [36].
We previously showed that IL-18 acts on endothelial
cells to induce angiogenesis and cell adhesion [37,38]. A
primary source of IL-18 is the macrophage; however, var-
ious other sources of IL-18 have been identified, includ-
ing Kupffer cells, dendritic cells, keratinocytes, articular
chondrocytes, osteoblasts, and synovial fibroblasts
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Page 2 of 14[5,37,39-45]. The IL-18 receptor (IL-18R) is similarly
expressed on many cell types, including T lymphocytes,
natural killer cells, macrophages, neutrophils, and chon-
drocytes [31,32,40,46], underscoring the pleiotropic
nature of this receptor-ligand pair.
IL-18 has structural homology with IL-1, shares some
common signaling pathways [37,47], and also requires the
cleavage at its aspartic acid residue by IL-1-converting
enzyme to become an active, mature protein [37,48,49].
Thus, IL-1 and IL-18 share many biologically similar
inflammatory functions. Previous work implicated IL-18
in RA, as higher levels are present in RA compared with
osteoarthritic synovial fluid (SF) and sera [5,37]. Also, IL-
18 enhances erosive, inflammatory arthritis in murine
models of systemic arthritis [5,37]. The influential role of
IL-18 in articular inflammation was confirmed in mice
lacking the IL-18 gene that had reduced the incidence and
severity of collagen-induced arthritis (CIA), which was
reversed by treatment with recombinant human (rhu) IL-
18 [37,50]. With mice deficient in IL-18, CIA was less
severe compared that in wild-type (Wt) mice [1,50], con-
firmed by histologic evidence of decreased joint inflam-
mation and destruction. Furthermore, levels of bovine
collagen-induced IFN-γ, TNF-α, IL-6, and IL-12 from
spleen cell cultures were correspondingly decreased in
IL-18-deficient animals [1].
Blocking of IL-18 was also tested in CIA [1,51-53]. Wt
DBA-1 mice were treated with either neutralizing anti-
bodies to IL-18 or the IL-18-binding protein (IL-18BP)
after clinical onset of disease, resulting in significantly
reduced joint inflammation and reduced cartilage erosion
[1,53]. In streptococcal cell wall (SCW)-induced arthritis
[1,54], neutralizing rabbit anti-murine IL-18 antibody
suppressed joint swelling. This effect was noted early,
after blockade of endogenous IL-18, and resulted in
reduced joint TNF-α and IL-1 levels [1]. These studies
clearly established a pathologic role for endogenous IL-18
in rodent arthritis. The effect of IL-18 was apparently
independent of IFN-γ, because anti-IL-18 antibodies
could equally inhibit SCW arthritis in mice deficient in
IFN-γ [1,55].
This study was carried out to define better the cellular
mechanisms induced by IL-18 contributing to the
observed pathology in many of these rodent models. We
clarified the cytokines induced by IL-18 in zymosan-
induced arthritis (ZIA) by comparing cytokine levels
from ZIA arthritic joints homogenized from IL-18 gene-
knockout and Wt mice. We also defined the role of IL-18
to recruit monocytes to human RA ST and murine lymph
nodes (LNs) in a severe combined immunodeficient
(SCID) mouse chimera. This confirmed many of our in
vitro chemotaxis findings showing that IL-18 induces
monocyte chemotaxis, and that this migratory property
is mediated by intracellular monocyte p38 and ERK½.
Materials and methods
Patient samples
Peripheral blood (PB) was obtained from healthy normal
(NL) volunteers. STs were obtained from RA patients
undergoing total joint replacement who met the Ameri-
can College of Rheumatology criteria for the classifica-
tion of RA. All tissues were obtained with informed
consent with Institutional Review Board approval.
Monocyte isolation
PB was collected in heparinized tubes from NL adult
donors. After centrifugation, the buffy coat was collected,
and mononuclear cells were purified under sterile condi-
tions on an Accu-Prep gradient at 400 g for 30 minutes at
room temperature. Mononuclear cells collected at the
interface were washed twice with PBS and resuspended
in Hank's Balanced Saline Solution (HBSS) with calcium
and magnesium (Life Technologies, Bethesda, MD, USA)
at 2.5 × 106 cells/ml. Mononuclear cell viability was rou-
tinely greater than 98% (purity > 99%), as determined
with trypan blue exclusion. Monocyte separation was
done by adding 4 ml of mononuclear cells mixed with 8
ml of isolation buffer (1.65 ml 10 × HBSS in 10 ml of Per-
coll, pH 7.0) in a 15-ml siliconized tube. After centrifuga-
tion (400 g for 25 minutes at room temperature),
monocytes were collected from the top layer of solution
(5 mm). Monocytes were > 95% pure, and viability was
>98% by trypan blue exclusion.
In vitro monocyte migration assay
Chemotaxis assays were performed by using a 48-well
modified Boyden chamber system, as done previously
[34,35]. Stimulant (25 μl) of IL-18 was added to the bot-
tom wells of the chambers, whereas 40 μl of human
monocytes from NL PB at 2.5 × 106 cells/ml was placed in
the wells at the top of the chamber. Sample groups were
assayed in quadruplicate, with results expressed as cells
migrated per high-power field (hpf; 400 ×). Hank's Bal-
anced Saline Solution (HBSS) and fMLP (10-7 M) were
used as negative and positive stimuli, respectively. The
rhuIL-18 used in all studies was purchased from MBL
International Corp., through R & D Systems (Minneapo-
lis, MN, USA). The endotoxin levels were < 0.1 ng/μg of
rhuIL-18 protein that, in our hands, did not previously
interfere with in vitro cell-migration experiments [37].
Monocyte culture and lysis
PB was collected in heparinized tubes, and monocytes
were isolated as described earlier and as we have done
previously [56]. Monocytes were plated in six-well plates
(5 × 106 cells/well) in serum-free RPMI. Cells were
allowed to attach for 1 hour at 37°C. Fresh RPMI was
used to rinse unattached cells. RPMI containing rhIL-18
was added to each well in a time-course manner, at time
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receiving no IL-18 (0 minutes). Medium was removed,
and 150 μl of cell-lysis buffer was added to each well.
Plates were kept on ice for 15 minutes with occasional
rocking. A cell scraper was used remove all cells, and
lysates were removed to an Eppendorf centrifuge tube.
Lysates were sonicated for 30 seconds, vortexed briefly,
and spun at 10,000 RPM for 10 minutes. Supernatants
were removed, measured for protein level (BCA protein
assay; Pierce Biotechnology, Rockford, IL, USA), and the
volume measured. Samples were frozen at -80°C until
assayed.
SDS-PAGE and Western blotting
Protein lysate (15 to 20 μg) from monocytes was run on
SDS-PAGE and transblotted to nitrocellulose membranes
by using a semi-dry transblotting apparatus (Bio-Rad,
Hercules, CA, USA). Nitrocellulose membranes were
blocked with 5% nonfat milk in Tris-buffered saline
Tween-20 (TBST) for 60 minutes at room temperature.
Blots were incubated with optimally diluted specific pri-
mary antibody in TBST containing 5% nonfat milk over-
night at 4°C. Phosphorylation state-specific antibodies
for ERK½ and p38 (Cell Signaling Technology Inc., Dan-
vers, MA, USA) were used as primary antibodies. Pri-
mary antibodies used for phospho-p38 (p-p38) MAPK
were rabbit anti-human Ab (9211; Cell Signaling) or p38
MAPK (for total p38) rabbit anti-human Ab (9212; Cell
Signaling). For ERK½ signaling, the primary antibodies
used were phospho-p44/42 MAPK (ERK½) rabbit anti-
human Ab (4370; Cell Signaling) or p44/42 MAPK (for
total ERK½) rabbit anti-human Ab (9102; Cell Signaling).
The secondary antibody used for detection of all signal-
ing molecules was anti-rabbit IgG, horseradish peroxi-
dase (HRP)-linked Ab (7074; Cell Signaling). Blots were
washed 3 times and incubated with the HRP-conjugated
antibody (1:1,000 dilutions) for 1 hour at room tempera-
ture. Protein bands were detected by using ECL (Amer-
sham Biosciences, Pittsburgh, PA, USA) per the
manufacturer's instructions. Blots were scanned and ana-
lyzed for band intensities by using UN-SCAN-IT version
5.1 software (Silk Scientific, Orem, UT, USA).
Transient transfection of human monocytes
Isolated human PB monocytes were plated in six-well
plates at 2.5 × 106 cells/ml with serum-free RPMI 1640
medium overnight and subsequently transfected by using
Lipofectin reagent (Invitrogen Inc., Carlsbad, CA, USA).
ODN DNA (10 μM) and Lipofectin (5 μl) were incubated
separately in 100 μl of serum-free medium for 30 min-
utes. Solutions were mixed gently, and 880 μl of medium
was added. A DNA/Lipofectin mixture was added to the
preincubated monocytes with an additional incubation of
≥ 5 hours before use in chemotaxis studies. Transfection
efficiencies for all ODNs used in this study were deter-
mined by counting FITC-transfected cells by fluores-
cence microscopy and comparing them with a DAPI label
in the same cells. Transfection of ODNs peaked at 5
hours with an efficiency routinely > 80% (data not
shown). For transient transfection of human monocytes,
the sense and antisense ODNs that were used with subse-
quent rhuIL-18 stimulation for in vivo migration assays
were ERK½ sense: ATGGCGGCGGCGGC; ERK½ anti-
sense: GCCGCCGCCGCCAT [57]; JNK sense: GCT
AAGCGGTCAAGGTTGAG; JNK antisense: GCTCAG
TGGACATGGATGAG [58]; Jak2 sense: ATGGGAATG-
GCCTGCCTT; Jak2 antisense: AAGGCA GGCCATTC-
CCAT [59]; p38 sense: AGCTGATCTGGCCTACAGTT;
p38 antisense: AGGTGCTCAGGACTCCATTT [60].
Transfected cells were used in in vitro monocyte chemot-
axis studies.
Human ST collection
STs were obtained from RA patients undergoing total
joint replacement who met the American College of
Rheumatology criteria for RA. Under sterile conditions,
RA ST was isolated from surrounding tissue, cut into 0.5-
cm3 segments, and screened for pathogens before
implantation. All tissues were stored frozen at -80°C in a
freezing medium (80% heat-inactivated fetal bovine
serum with 20% dimethyl sulfoxide, vol/vol), thawed and
washed three times with PBS before insertion into mice.
All specimens were obtained with IRB approval.
Mice
Animal care at the Unit for Laboratory Animal Medicine
at the University of Michigan is supervised by a veterinar-
ian and operates in accordance with federal regulations.
Wt and IL-18 gene knockout mice were bred in house
according to the guidelines of the University Committee
on the Use and Care of Animals. SCID/NCr mice were
purchased from the National Cancer Institute (NCI). All
mice were given food and water ad libitum throughout
the entire study and were housed in sterile rodent microi-
solator caging with filtered cage tops in a specific patho-
gen-free environment to prevent infection. All efforts
were made to reduce stress or discomfort in the animals
used in these studies.
Monocyte isolation and fluorescent dye incorporation
Human monocytes were isolated from the PB (~100 ml)
of NL healthy adult volunteers and applied to Ficoll gradi-
ents, as previously described [56]. Monocyte viability and
purity of cells was routinely > 90%. For in vivo studies,
monocytes were fluorescently dye-tagged with PKH26 by
using a dye kit per manufacturer's instructions (Sigma-
Aldrich, St. Louis, MO, USA). Successful labeling of
monocytes was confirmed by performing cytospin analy-
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scope equipped with a 550-nm filter.
Generating human RA ST SCID mouse chimeras
SCID mouse human RA ST chimeras represent a unique
way to study human tissue in vivo. We used this model to
study whether intragraft-administered rhuIL-18 can
recruit monocytes in vivo. Six- to eight-week-old immu-
nodeficient mice were anesthetized with isoflurane under
a fume hood, after which a 1.5-cm incision was made
with a sterile scalpel on the midline of the back. Forceps
were used bluntly to dissect a path for insertion of the ST
graft. ST grafts were implanted on the graft-bed site and
sutured by using surgical nylon. Grafts were allowed to
"take," and the sutures were removed after 7 to 14 days.
Within 4 to 6 weeks of graft transplantation, rhuIL-18
was injected into grafts. Grafts injected intragraft with
PBS served as a negative control. Immediately thereafter,
mice were administered 5 × 106 fluorescently dye-tagged
(PKH26) human PB monocytes through the tail vein.
Mice were killed, and grafts were harvested 48 hours
later. For all in vivo studies, integrated human monocytes
to the implanted ST were examined from cryosectioned
slides by using a fluorescence microscope and scored
[61]. Murine LNs were fluorescently stained for human
CD4-, CD11b/Mac-1-, CD14-, and CD19-expressing
cells. For monocyte detection, the primary antibody was
a mouse anti-human mAb (mouse anti-human CD11b/
Mac-1 from BD Biosciences Pharmingen, San Jose, CA,
USA; catalog no. 555385), followed by blocking with goat
serum and the addition of a goat anti-mouse FITC-tagged
secondary antibody (goat anti-mouse FITC IgG, Sigma-
Aldrich; catalog no. 025K6046). Murine LN tissues were
similarly stained for human lymphocyte CD4 (T-cell; pri-
mary mAb from BD Biosciences Pharmingen; catalog no.
3015A) and CD19 (B-cell; primary mAb from BD Biosci-
ences Pharmingen; catalog no. 555410) followed with the
corresponding FITC-tagged secondary antibody (Sigma-
Aldrich). All sections were analyzed appropriately, and
evaluators were blinded to the experimental setup.
ZIA induction
Wt (13 mice) and IL-18 gene-knockout mice (12 mice)
were divided into two separate groups, with one group
receiving PBS and the other receiving zymosan (Sigma-
Aldrich). Before the procedure, all mice were anesthe-
tized with 0.08 ml of ketamine and subsequently received
20 μl/knee joint (both knees/mouse) of either PBS or
zymosan (30 mg/ml). Mice were allowed to recover and
were measured for joint circumference, as described pre-
viously [62]. Circumference measurements were taken at
24 hours for all mice, and at 48 hours for the remaining
mice. After killing, all mice were bled for serum, and then
the knees were taken for homogenate preparation and
cytokine analysis.
Clinical assessment of murine ZIA
Clinical parameters of ZIA mice were assessed at 24 and
48 hours after zymosan injection and included ankle cir-
cumference, as previously described for rat AIA [62]. For
ankle-circumference determination, two perpendicular
diameters of the joint were measured with a caliper
(Lange Caliper; Cambridge Scientific Industries, Cam-
bridge, MA, USA). Ankle circumference was determined
by using the geometric formula: circumference = 2 π
(√(a2 + b2/2)), where a is the laterolateral diameter, and b
is the anteroposterior diameter.
ZIA joint homogenate preparation
Wt and IL-18 gene-knockout mice were killed, and joints
and serum were collected at 24 and 48 hours after zymo-
san administration. Only hind joints were used in the
study. Joints were removed directly below the hairline
and snap frozen in liquid nitrogen. All joints were stored
at -80°C before processing. Each joint was thawed on ice
and quickly homogenized on ice in 1 to 2 ml phosphate-
buffered saline (PBS) containing a tablet of proteinase
inhibitors (10-ml PBS/tablet; Boehringer Mannheim,
Indianapolis, IN, USA). Homogenized tissues were cen-
trifuged at 2,000 g at 4°C for 10 minutes, filtered, ali-
quoted, and stored at -80°C until analysis with ELISA.
ELISA technique
ELISA assays were performed as described previously
[34]. In brief, cytokine levels from ZIA mouse-joint
homogenates were measured by coating 96-well polysty-
rene plates with anti-murine chemokine antibodies (R &
D Systems, Minneapolis, MN, USA) followed by a block-
ing step. Cytokines measured were IL-1β IL-6, IL-17,
TNF-α MCP-1/CCL2, MIP-1α/CCL3, MIP-3α/CCL20,
RANTES/CCL5, and VEGF. All samples were added in
triplicate, with rhuIL-18 as standard. Subsequently, bioti-
nylated anti-human antibody and streptavidin peroxidase
were added, and sample concentrations were measured at
450 nm after developing the reaction with TMB sub-
strate.
Statistical analysis
Statistical significance values for all studies were calcu-
lated by using the Student t test. Values of P < 0.05 were
considered statistically significant.
Results
IL-18 is chemotactic for monocytes
Monocytes were isolated from the PB of NL volunteers
and tested for migratory activity in a modified Boyden
chemotaxis system. Figure 1 shows that monocytes read-
ily migrate toward recombinant human IL-18 in a dose-
dependent fashion, starting at 0.25 nM up to 25 nM. This
indicates that IL-18 is chemotactic at concentrations sim-
ilar to those found in RA SF [5].
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To define the kinetics of monocyte signaling pathways
due to IL-18 stimulation, we used Western blots and
examined four signaling pathways. Pathways tested were
Jak2, JNK, p38, and ERK½. As shown in Figure 2, p-p38
was upregulated early at 5 minutes after IL-18 stimula-
tion (upper panel). The effect was lost thereafter. p-ERK½
was upregulated by 15 minutes and showed maximal
expression by 30 minutes (lower panel). Other signaling
pathways, including Jak2 and JNK, were examined, but
showed no significant expression resulting from IL-18
stimulation (data not shown). Graphs for p-p38 and p-
ERK½ were normalized by respective total cellular
expression for both signaling molecules relative to the
untreated control blots.
From these findings, IL-18 appears to stimulate mono-
cytes through the p38 and ERK½ pathway, suggesting that
disruption of this pathway could mediate IL-18 stimula-
tory activity on monocyte function. Blots were normal-
ized to total p38 and ERK½, respectively (representative
blots shown). In total, five separate experiments were
completed by using PB monocytes from four separate
volunteers.
Inhibition of p38 and ERK½ by ODN tranfection reduces 
monocyte chemotaxis to IL-18
We wanted to link signal-transduction pathways to
monocyte function as a result of IL-18 stimulation. To do
this, we inhibited both the p38 and ERK½ pathways with
ODNs to each signaling molecule. Anti-sense ODN
knockdown efficiency of intended targets was confirmed,
as previously described [61]. We then tested the ability of
rhuIL-18 (2.5 nM) to recruit PB monocytes as it did pre-
viously (Figure 1). As shown, transfection of monocytes
with either antisense p38 or ERK½ significantly reduced
the monocyte chemotactic activity of IL-18 compared
with sense (nonspecific) ODN transfection (Figure 3).
Jak2 and JNK were similarly inhibited but did not result
in reductions of IL-18-stimulated monocyte chemotaxis
(data not shown).
IL-18 induces monocyte recruitment to synovium and LNs 
in the RA ST SCID mouse chimera
To test monocyte migration in vivo, we used an RA ST
SCID mouse chimera model. After 4 to 6 weeks, animals
engrafted with human RA ST showing no signs of rejec-
tion were used, as done previously [61]. To determine
homing of NL human PB monocytes to RA ST in vivo,
freshly isolated cells were fluorescently dye-tagged with
PKH26, and 5 × 106 cells/100 μl/mouse were injected i.v.
(tail vein) 48 hours before killing. Immediately after
administration of dye-tagged cells, engrafted SCID mice
received intragraft injections of rhIL-18 (1 μg/ml) or an
equal volume of PBS. After 2 days, RA ST grafts and
murine inguinal LNs were removed, and cryosections of
tissues (10 μm) were examined by using a fluorescence
microscope. The total number of mice used is indicated
on the graph, with the "n" corresponding to the total
number of sections analyzed from each treatment group.
At least 12 sections/group, representing grafts taken from
all the mice, were evaluated. Results from each section
were average and divided by the number of hpfs (100 ×),
to determine the number of migrating cells/hpf, as done
previously [61]. Care was taken to represent each graft as
equally as possible. Results are shown in Figure 4(a). IL-
18, when administered intragraft, induced robust mono-
cyte recruitment to both the RA ST grafts and local LNs
(see arrows). In (b), graphs of both the RA ST and LN
data clearly show that mice receiving IL-18 intragraft
injections had significantly increased numbers of mono-
cytes recruited to both implanted RA ST and local
murine LN tissue in the SCID chimera system. In (c), to
confirm that migrating cells to murine LNs were human
monocytes, LNs from rhuIL-18-simulated SCID chimeric
mice were harvested and evaluated for human monocyte
recruitment. LNs were stained for CD11b/Mac-1 with
fluorescence histology. The primary antibody was a
mouse anti-human mAb, followed by blocking with goat
serum and the addition of a goat anti-mouse FITC-tagged
secondary antibody. (a) Human monocytes expressing
CD11b/Mac-1 migrate to murine LNs (fluorescent green
cells, see arrow). (b) Fluorescent dye-tagged human cells
in murine LNs. (c) Merger of (a) and (b) showing that the
migrating cells are expressing human CD11b/Mac-1 (flu-
orescent yellow staining, see arrow). (d) DAPI staining
showing cell nuclei (fluorescent blue cells, see arrow). (e)
Negative control staining for CD11b/Mac-1 (non-specific
Figure 1 Monocytes were isolated from the peripheral blood (PB) 
of normal (NL) volunteers and placed in a modified Boyden 
chemotaxis system opposite graded increases in concentration 
of rhuIL-18. As shown, IL-18 stimulates chemotaxis for human mono-
cytes in a dose-dependent manner, and is maximal between 0.25 nM 
and 25 nM (figure representative of three separate experiments).
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Figure 2 IL-18 activates p-p38 and p-ERK½ in a time-dependent manner. Monocytes (5 × 106 cells) were stimulated with 2.5 nM rhuIL-18. Cell 
lysates were made and probed for p-p38 and p-ERK½ with Western blot, showing marked increases in phosphorylation after 5 minutes for p-p38 and 
15 to 30 minutes for p-ERK½. Representative blots show both p-p38 and p-ERK½ (upper panel for p-p38 and lower panel for p-ERK½). Graphs for p-
p38 and p-ERK½ were normalized by respective total cellular expression for both signaling molecules relative to the untreated control blots (n = the 
number of blood donors, and graphs show combined data from five separate experiments). In total, five separate experiments were completed by 
using peripheral blood monocytes from four separate volunteers.
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Page 7 of 14IgG was used as the primary mAb). (f ) Murine LN show-
ing recruited cells (red fluorescent staining, see arrow).
(g) Merger of (e) and (f ) showing a lack of nonspecific cel-
lular staining. (h) DAPI staining showing cell nuclei (orig-
inal magnification, 400×). Murine LN tissues were
similarly stained for human CD4 and CD19 expression,
but were negative for staining (data not shown).
IL-18 gene-knockout mice have reduced ZIA-induced joint 
inflammation compared with Wt mice
The better to define the activity of IL-18 to induce inflam-
matory responses in acute models of arthritis, we admin-
istered to both Wt and IL-18 gene-knockout mice a single
intraarticular (i.a.) injection of zymosan, inducing ZIA
over a 48-hour period. Mice were divided into two sepa-
rate groups and killed at either 24 or 48 hours. All mice
were examined for joint swelling 24 hours later, and a
smaller cohort containing the remainder of the mice was
examined at 48 hours. IL-18 gene-knockout mice showed
significant reductions of joint swelling as early as 24
hours, and this continued for up to 48 hours after ZIA
induction (Figure 5). Notable increases in joint swelling
were observed in both the Wt and IL-18 gene-knockout
groups at 48 hours compared with 24 hours, with IL-18
deletion profoundly reducing joint swelling compared
with that in Wt mice at both time points. These data sug-
gest that IL-18 is produced early in the course of arthritic
inflammation, indicating that it may be essential for stim-
ulation of a proinflammatory cytokine cascade during
acute inflammatory responses.
Cytokine expression from sera and joint homogenates of 
ZIA mice
After killing, ZIA mouse serum and joints were har-
vested, and joint tissue was homogenized. Joint homoge-
nates were measured for total protein content and
assayed with ELISA for cytokines, including IL-1β IL-6,
IL-17, TNF-α monocyte chemotactic protein-1 (MCP-1)/
CCL2, macrophage inflammatory protein-1α MIP-1α/
CCL3), MIP-3α/CCL20, regulated on activation normally
T-cell expressed and secreted (RANTES)/CCL5, and vas-
cular endothelial cell growth factor (VEGF). For compari-
sons, all cytokines measured were normalized to the total
protein content of each homogenate. As shown in Figure
6, all mice showed detectable levels in joint homogenates
of all cytokines tested; however, ZIA IL-18 gene-knock-
out mice showed significant reductions in IL-17 (a),
VEGF (b), and MIP-3α/CCL20 (c) compared with ZIA
Wt mice, indicating that expression of IL-18 can initiate
proinflammatory cytokine release in joints during acute
arthritis. Alternatively, homogenates from IL-18 gene-
knockout mice increased MCP-1/CCL2 (JE) levels (d)
due to zymosan injection compared with Wt mice, indi-
cating that the expression of some monocyte recruitment
factors may actually be inhibited because of the presence
of IL-18. Sera from all groups of mice showed no signifi-
cant differences in cytokine levels tested between the Wt
and IL-18 gene-knockout mice induced for ZIA.
Discussion
Our data show that IL-18 recruits monocytes in vivo, may
be produced early in the acute phase of arthritis, and sig-
nals via p38 and ERK½ to recruit PB monocytes to STs.
IL-18 is known to function in an autocrine or paracrine
fashion, and increased expression of IL-18 in the syn-
ovium may play a critical role for development of synovial
inflammation, synovial hyperplasia, and articular degra-
dation to which angiogenesis may contribute [37]. Given
the importance of angiogenesis in the pathophysiology of
RA, we previously demonstrated a role for IL-18 as an
angiogenic mediator [37]. Supportive of this function was
the finding that IL-18 has been shown to stimulate pro-
duction of angiogenic TNF-α [37,63].
We previously examined the signal-transduction mech-
anisms by which IL-18 induces vascular cell adhesion
molecule-1 (VCAM-1) expression in RA synovial fibro-
blasts [31]. In that study, we outlined how IL-18 signals
through the IL-18R complex composed of both α and β
chains. Concerning the IL-18R complex, the IL-18Rα
chain is the extracellular binding domain, whereas the IL-
18Rβ is the signal-transducing chain. When bound to the
IL-18R, IL-18 induces the formation of an IL-1R-associ-
ated kinase (IRAK)/TNF receptor-associated factor-6
(TRAF-6), a multipart structure that has stimulatory
activity for nuclear factor κB (NF-κB) in Th1 cells [47] and
Figure 3 Monocytes were suspended at 2.5 × 106 cells/ml and 
then transfected with sense or antisense ODNs in serum-free me-
dia for 4 hours. Transfection efficiency for all genes was routinely > 
80%, as determined by counting fluorescein isothiocyanate (FITC)-
transfected cells with fluorescence microscopy and comparing with a 
DAPI label in the same cells (data not shown). Transfected cells were 
added to Boyden chemotaxis chambers to determine their migratory 
activity toward rhuIL-18 (2.5 nM). As shown, monocytes transfected 
with either antisense p38 or ERK½ showed significant reductions in 
chemotaxic activity toward rhuIL-18 compared with sense transfected 
cells (n = number of experimental repeats from independent PB 
monocyte donors).
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Figure 4 Peripheral blood monocytes injection. (A) PKH26 red fluorescent dye-tagged human peripheral blood (PB) monocytes (5 × 106) were in-
jected i.v. into SCID mice engrafted for 4 to 6 weeks with human rheumatoid arthritis synovial tissue (RA ST). Before administering cells, ST grafts were 
injected with rhuIL-18 (1,000 ng/graft) or sham injected (PBS stimulus). At 48 hours, grafts and inguinal lymph nodes (LNs) were harvested, and tissue 
sections were examined with immunofluorescence microscopy at 550 nm (100 ×). The top panel shows PKH26 dye-tagged monocytes migrating into 
PBS or rhuIL-18 injected RA ST. (B) The lower portion of the same panel shows an image of the local LNs containing recruited monocytes from the 
same mice. The number of dye-tagged cells migrating to engrafted RA ST or LN tissue in response to rhuIL-18 is graphed in the next panel. As shown, 
SCID mice receiving intragraft injections of rhuIL-18 showed significant recruitment of human monocytes to both engrafted RA ST and murine LNs. 
Monocyte migration was quantified by dividing the number of cells per hpf/tissue section at 100 × (n = number of tissue sections counted ± SEM). 
(C) LNs from rhuIL-18 simulated SCID chimeric mice were harvested and evaluated for human monocyte recruitment. LNs were stained for CD11b/
Mac-1 with fluorescence histology. The primary antibody was a mouse anti-human mAb, followed by blocking with goat serum and the addition of 
a goat anti-mouse FITC-tagged secondary antibody. (a) Human monocytes expressing CD11b/Mac-1 migrate to murine LNs (fluorescent green cells, 
see arrow). (b) Fluorescent dye-tagged human cells in murine LNs. (c) Merger of (a) and (b), showing that the migrating cells are expressing human 
CD11b/Mac-1 (fluorescent yellow staining; see arrow). (d) DAPI staining showing cell nuclei (fluorescent blue cells, see arrow). (e) Negative-control 
staining for CD11b/Mac-1 (nonspecific IgG was used as the primary mAb). (f) Murine LN showing recruited cells (red fluorescent staining, see arrow). 
(g) Merger of (e) and (f) showing a lack of nonspecific cellular staining. (h) DAPI staining showing cell nuclei (original magnification, 400 ×).
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Page 9 of 14in EL4/6.1 thymoma cells [31,64]. From our previous
findings, we demonstrated that IL-18 induces VCAM-1
expression through Src kinase, PI3-kinase/Akt, and
ERK½ signaling pathways [31], and outlined the partici-
pation of the IRAK/NF-κB pathway in RA synovial fibro-
blast VCAM-1 expression.
Dinarello and colleagues [65] showed that distinct dif-
ferences exist in IL-1 and IL-18 signaling in transfected
human epithelial cells, and that IL-1 signaling is primarily
through the NF-κB pathway, whereas IL-18 signals via the
MAPK p38 pathway. This finding may account for the
absence of cyclooxygenase from IL-18-stimulated human
epithelial cells and may explain the inability of IL-18 to
induce fever, unlike IL-1 [65]. These findings also support
our current signaling data showing that IL-18 induces
p38 and ERK½ pathways in monocytes, confirmed by sig-
naling inhibitory studies, Western blotting, and kinetic
analysis showing that p38 is upregulated early in mono-
cytes stimulated by IL-18, with subsequent upregulation
of ERK½.
We also investigated a novel function of IL-18 to recruit
monocytes in vitro and in vivo. Our in vitro data showed
IL-18 chemotaxic activity for monocytes at levels of IL-18
similar to those found in RA SF [5]. We previously evalu-
ated the role of IL-18 as an angiogenic mediator and
showed that HMVECs respond to rhuIL-18 in a modified
Boyden chemotaxis system [37]. For the current study, we
purchased the rhuIL-18 from the same vendor with the
exact specifics regarding sample purity. Our monocyte
chemotaxis findings correlate well with other studies
showing IL-18 to be chemotactic for human T cells and
dendritic cells [66,67]. We also showed that at elevated
levels beyond that found in the RA SF, IL-18 appears to be
inhibitory for monocyte migration, similar to what we
found in previous studies investigating MIP-3α and
CXCL16 [35,61]. This is likely due to a regulatory feed-
back loop tempering cytokine function in acute and
chronic inflammatory responses.
We then attempted to link the signaling data with in
vitro monocyte migration findings by inhibiting mono-
cyte p38 and/or ERK½ with ODNs, and then tested
monocyte migratory activity toward IL-18 in a modified
Boyden chemotaxis system. We show that disruption of
IL-18-induced monocyte signaling using antisense ODNs
confirmed our earlier observations of induced monocyte
p38 and ERK½ activation by IL-18, resulting in signifi-
cantly reduced monocyte chemotaxis. Although we did
not demonstrate a direct effect of IL-18 by inhibition of
downstream kinases, we did show that inhibition of
kinases activated by IL-18 can alter monocyte migration
toward IL-18 in a dose-dependent manner.
From these in vitro findings, further examination of the
contribution of IL-18 in monocyte chemotaxis in an
SCID mouse chimera system was warranted. To do this,
SCID mice engrafted with RA ST received intragraft
injections of rhuIL-18 with immediate administration of
PB monocytes isolated, fluorescently dye tagged, and
injected i.v. into chimeric mice, as done previously [61].
In this setting, IL-18 proved to be a robust monocyte
chemotactic agent, directing migration of human mono-
cytes not only to engrafted ST, but also to local (inguinal)
murine LNs.
Data from the SCID mouse chimera provided circum-
stantial evidence that IL-18 may be an effective monocyte
recruitment factor in chronic diseases and supported
previous findings that IL-18 gene-knockout mice have
reduced inflammation in relevant models of RA [1].
Rodent models of arthritis are indeed useful tools for
studying the pathogenic process of RA. Although no
model perfectly duplicates the condition of human RA,
they are easily reproducible, well defined, and have
proven useful for development of new therapies for
arthritis, as exemplified by cytokine-blockade therapies.
Furthermore, time-course studies consistently found that
IL-1β, IL-6, TNF-α and other key pro-inflammatory
cytokines and chemokines are functional in a variety of
models, including CIA, adjuvant induced arthritis (AIA),
SCW, and immune complex arthritis [68].
Notably, proinflammatory IL-18 activity has been
extensively examined in CIA, an accepted animal model
of RA, as it shares many immunologic and pathologic fea-
tures of human RA [68]. This model is reproducible in
genetically susceptible strains of mice with major histo-
compatibility haplotypes H-2q or H-2r by immunization
with heterologous type II collagen in Complete Freund's
Adjuvant. Susceptible strains are DBA/1, B10.Q, and
B10.RIII [68]. Drawbacks of this model are that, in some
Figure 5 Wt and IL-18 gene-knockout mice were administered zy-
mosan to induce zymosan-induced arthritis (ZIA). Wt mice showed 
increases of hind joint (knee) circumference from 24 to 48 hours, with 
a pronounced reduction of swelling in comparative mice lacking IL-18. 
These data show that IL-18 is critical in acute inflammation of murine 
joints in as early as 24 hours after zymosan injection (n = number of 
joints analyzed).
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Page 10 of 14studies, roughly a third of the mice do not develop arthri-
tis, inherent inconsistencies in CIA progression, and that
murine CIA can take a substantial time to develop, some-
times as much as 6 to 8 weeks. In addition, many gene-
knockout strains are available only on the C57BL/6 back-
ground, a strain resistant to development of CIA. Despite
the many hurdles, IL-18 has been shown to play a central
role in CIA [1,50,69,70]. When injected into DBA-1 mice
immunized with collagen in incomplete Freund's adju-
vant, IL-18 increased the erosive and inflammatory com-
ponent of the condition [1,5]. Using mice deficient in IL-
18, CIA was less severe compared with Wt controls
[1,50], and histologic evidence of decreased joint inflam-
mation and destruction also was observed, outlining a
direct pathologic role for IL-18.
We chose to use the ZIA model to examine the partici-
pation of IL-18 to induce a cytokine cascade by using IL-
18 gene-knockout mice. Murine ZIA was first character-
ized by Keystone in 1977 [71]. This model is simple and
straightforward, with arthritis induction initiated by a
single i.a. injection of zymosan. Of note is that ZIA
apparently lacks significant lymphocyte involvement and
is therefore not well suited for experiments designed for
examining T-cell or B-cell function in arthritis develop-
ment. ZIA was chosen for this study primarily because of
the timeliness of the inflammatory response and because
IL-18, a monokine, is not known to be highly dependent
on lymphocyte activation.
Zymosan is a polysaccharide from the cell wall of Sac-
charomyces cerevisiae. Zymosan is composed primarily of
glucan and mannan residues [72,73]. In vitro, it has
served as a model for the study of innate immune
responses, such as macrophage and complement activa-
tion [74,75]. Zymosan is also recognized and phagocy-
Figure 6 Joint homogenates were prepared from both Wt and IL-18 gene-knockout mice injected with zymosan to induce zymosan-in-
duced arthritis (ZIA). All tissue homogenates were initially measured for total protein content to normalize cytokine expression to total protein con-
tent for comparison between cytokines. Cytokines measured included IL-1β IL-6, IL-17, TNF-α MCP-1/CCL2, MIP-1α/CCL3, MIP-3α/CCL20, RANTES/
CCL5, and VEGF. Although all cytokines measured were detectable in all the tissue homogenates, significant decreases of IL-17 (a), VEGF (b), and MIP-
3α/CCL20 (c) were found in the IL-18 gene-knockout homogenates compared with Wt mice. Conversely, MCP-1/CCL2 (d) was significantly increased 
in the same homogenates from IL-18 gene-knockout compared with Wt mice (n = number of joints examined)
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Page 11 of 14tosed principally by monocytes and macrophages and
leads to cellular activation and monokine production
[76], a nice feature when examining the participation of a
monokine in vivo. The subsequent inflammatory
response is thought to be mediated by activation of the
alternative pathway of complement and the release of lys-
osomal hydrolases from activated macrophages [77].
Increasing evidence suggests that Toll-like receptors may
also be involved [72]. The advantages of ZIA include its
simplicity and the fact that the resultant inflammation it
induces is not strain specific. ZIA also affords the oppor-
tunity to investigate cytokines involved in joint inflam-
mation during an acute response that may offer insight
into early proinflammatory cytokine release in the initial
phases of the inflammatory response. This is often lost by
using models such as CIA that normally take weeks to
develop [78].
Using ZIA, we observed significantly reduced joint
inflammation in IL-18 gene-knockout mice in as little as
24 hours after zymosan injection, and this trend contin-
ued for up to 48 hours.
We also found many proinflammatory cytokines simi-
larly reduced in the joint homogenates of IL-18 gene-
knockout mice, including IL-17, MIP-3α/CCL20, and
VEGF. Although, as indicated earlier, ZIA is not known to
be highly T-cell dependent, surprisingly, we found signifi-
cantly reduced IL-17 and MIP-3 CCL20 in IL-18 gene-
knockout ZIA joint homogenates, consistent with previ-
ous findings of CCR6, the MIP-3α/CCL20 receptor,
located on T helper17 (Th17) lymphocytes [35,79] This
interesting finding suggests that during certain acute
joint-inflammatory models, T-cell subsets may become
activated and express proinflammatory lymphokines. It is
tempting to speculate that during an acute inflammatory
response, Th17 cell subsets are activated and recruited to
the joint, which may explain the increase in IL-17 in the
joint homogenates of ZIA mice. This leads to the intrigu-
ing possibility that IL-18 may regulate Th17 responses by
directly supporting MIP-3α/CCL20 and IL-17 expression
in STs.
Also of note were the increased MCP-1/CCL2 levels in
joint homogenates from ZIA IL-18 gene-knockout mice.
This seemingly paradoxic finding can be explained by
noting that IL-18 may induce expression of an unidenti-
fied MCP-1/CCL2 inhibiter, much like the association of
TNF-α and IL-1-receptor antagonist protein (IL-1Ra). In
the latter system, it has been demonstrated in both
murine type-1 chronic pulmonary inflammatory models
and from treatment of RA patients with a chimeric
monoclonal antibody to TNF-α that TNF-α expression
supports inhibition of IL-1β by upregulation of IL-1Ra, a
natural antagonist of IL-1β [29,80]. We envision a similar
scenario involving a regulatory loop for IL-18 and MCP-
1/CCL2, as disruption of IL-18 significantly increased
local expression of MCP-1/CCL2.
Detection of VEGF regulation was somewhat surpris-
ing, given the acute nature of ZIA. As ZIA is not normally
thought of as a disease dependent on a high degree of
vasculature, it should be noted that the inflammatory
response observed in ZIA mice does indicate that proin-
flammatory cells are migrating freely from the peripheral
bloodstream into joint tissues, presumably aided by addi-
tional vasculature mediated by VEGF. Furthermore,
monocytes respond, produce, and migrate toward VEGF,
providing further evidence that recruited monocytes may
amplify the angiogenic process in acute inflammatory tis-
sues expressing IL-18. It is tempting to speculate that the
effects of VEGF on vasculature growth may exacerbate
the IL-18-induced pathology seen in murine ZIA.
We found that IL-18 stimulates monocyte migration
both in vitro and in an RA ST SCID mouse chimera sys-
tem. We further show that this is mediated by activation
of the p38 and ERK½ signaling pathway. We confirmed
the latter finding by use of ODNs designed to disrupt this
pathway and, in so doing, significantly reduced IL-18-
mediated monocyte chemotaxis. We also showed that IL-
18 gene-knockout mice have reduced ZIA, an acute
model of RA, and that mice lacking IL-18 have signifi-
cantly reduced joint homogenate levels of IL-17, MIP-3α/
CCL20, and VEGF
Overall, this study indicates that IL-18 is effective very
early in acute inflammatory models by inducing proin-
flammatory cytokine release and monocyte migration to
STs, lending support to the notion that IL-18 plays a hier-
archic role in the inflammatory cytokine cascade during
arthritis development.
Conclusions
We found that IL-18 stimulates monocyte migration both
in vitro and in an RA ST SCID mouse chimera system.
We further showed that this is mediated by activation of
the p38 and ERK½ signaling pathway. IL-18 gene =
knockout mice showed pronounced reductions in joint
inflammation during ZIA compared with Wt mice, indi-
cating that IL-18 may be produced in acute inflammatory
responses and may serve a hierarchic position for initiat-
ing joint inflammatory responses.
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